Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018

• Published in: Antimicrobial resistance & infection control Vol. 9; no. 1; p. 82
• Main Authors: Garcia-Jeldes, Hector Felipe, Mitchell, Robyn, McGeer, Allison, Rudnick, Wallis, Amaratunga, Kanchana, Vallabhaneni, Snigdha, Lockhart, Shawn R, Bharat, Amrita
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.06.2020; BioMed Central; BMC
• Subjects: Age; Aged; Alberta; Anopheles; Bacterial Proteins - metabolism; beta-Lactamases - metabolism; British Columbia; Canada; Canada - epidemiology; Candida; Candida - isolation & purification; Candida - metabolism; Candidiasis - epidemiology; Cross infection; Disease control; Drug resistance; Female; Fungal infections; Genomes; Health aspects; Health care; Hospitals; Humans; India; Intensive care; Male; Middle Aged; Nosocomial infections; Ontario; Patients; Prevalence; Quebec; Risk factors; Short Report; Surveillance; Transplants & implants; Travel; Canada; India; British Columbia; Alberta; Ontario; Quebec; United States > US; Cross infection; Drug resistance; Candida; Risk factors
• ISSN: 2047-2994; 2047-2994
• DOI: 10.1186/s13756-020-00752-3

To identify the prevalence of C. auris in Canadian patients who are potentially at risk for colonization, we screened 488 patients who were either hospitalized abroad, had a carbapenemase-producing organism (CPO), or were in units with high antifungal use. Two patients were colonized with C. auris; both had received healthcare in India and had a CPO. Among 35 patients who had recently received healthcare in the Indian subcontinent and were CPO colonized or infected, the prevalence of C. auris was 5.7%.